From the medical demo working experience with Xyrem in narcolepsy/cataplexy people at therapeutic doses, two clients documented stress and anxiety and just one described insomnia adhering to abrupt discontinuation within the termination from the clinical trial; in The 2 individuals with anxiousness, the frequency of cataplexy had increased markedly